1. Home
  2. ALDX vs VACH Comparison

ALDX vs VACH Comparison

Compare ALDX & VACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALDX
  • VACH
  • Stock Information
  • Founded
  • ALDX 2004
  • VACH 2023
  • Country
  • ALDX United States
  • VACH United States
  • Employees
  • ALDX N/A
  • VACH N/A
  • Industry
  • ALDX Biotechnology: Pharmaceutical Preparations
  • VACH
  • Sector
  • ALDX Health Care
  • VACH
  • Exchange
  • ALDX Nasdaq
  • VACH NYSE
  • Market Cap
  • ALDX 133.7M
  • VACH 324.2M
  • IPO Year
  • ALDX 2014
  • VACH 2024
  • Fundamental
  • Price
  • ALDX $2.16
  • VACH $10.29
  • Analyst Decision
  • ALDX Strong Buy
  • VACH
  • Analyst Count
  • ALDX 2
  • VACH 0
  • Target Price
  • ALDX $9.50
  • VACH N/A
  • AVG Volume (30 Days)
  • ALDX 1.5M
  • VACH 177.1K
  • Earning Date
  • ALDX 05-20-2025
  • VACH 01-01-0001
  • Dividend Yield
  • ALDX N/A
  • VACH N/A
  • EPS Growth
  • ALDX N/A
  • VACH N/A
  • EPS
  • ALDX N/A
  • VACH 0.26
  • Revenue
  • ALDX N/A
  • VACH N/A
  • Revenue This Year
  • ALDX N/A
  • VACH N/A
  • Revenue Next Year
  • ALDX N/A
  • VACH N/A
  • P/E Ratio
  • ALDX N/A
  • VACH $40.05
  • Revenue Growth
  • ALDX N/A
  • VACH N/A
  • 52 Week Low
  • ALDX $1.14
  • VACH $9.95
  • 52 Week High
  • ALDX $7.20
  • VACH $11.20
  • Technical
  • Relative Strength Index (RSI)
  • ALDX 34.82
  • VACH N/A
  • Support Level
  • ALDX $1.90
  • VACH N/A
  • Resistance Level
  • ALDX $2.89
  • VACH N/A
  • Average True Range (ATR)
  • ALDX 0.23
  • VACH 0.00
  • MACD
  • ALDX 0.10
  • VACH 0.00
  • Stochastic Oscillator
  • ALDX 26.26
  • VACH 0.00

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

About VACH VOYAGER ACQUISITION CORP.

Voyager Acquisition Corp is a blank check company.

Share on Social Networks: